摘要
目的:通过对子痫前期患者血清中的可溶性血管内皮生长因子受体1 (soluble fms-like tyrosine kinase-1,sFlt-1)和可溶性Endoglin(soluble Endoglin,sEng)的表达水平以及胎盘中Endoglin蛋白的表达水平的测定,探讨它们在子痫前期发病的作用、以及与子痫前期病情严重程度的关系。方法:选取2008年10月至2009年10月在泸州医学院附属医院住院分娩的子痫前期患者40例,按照乐杰主编的全国统编教材《妇产科学》第7版的诊断和分类标准进行分类,其中包括10例轻度子痫前期组,30例重度子痫前期组。选取同期健康孕妇40例作为对照组。采用酶联免疫吸附试验(ELISA)夹心法检测子痫前期患者与正常妊娠妇女血清中的sFlt-1和sEng的表达水平,了解两组间sFlt-1和sEng的表达是否存在差异。并通过免疫组化SP法测定子痫前期患者与正常妊娠妇女胎盘中Endoglin蛋白的表达水平来了解两组间Endoglin蛋白的表达水平是否存在差异,以及它与血清中sEng的关系。采用SPSS 14.0统计软件包进行统计学分析,数据以均数±标准差(x±s)表示;两样本均数比较用随机独立样本均数t检验;两变量间的相关关系用Pearson直线相关分析。取a=0.01作为检验水平,P<0.01差异有统计学意义。结果:1.子痫前期组血清sFlt-1为939.27±109.48ng/L,正常妊娠组为279.24±147.39ng/L,两组比较差异有显著性(p<0.01)。重度痫前期组血清中sFlt-1为941.76±159.01ng/L,轻度痫前期组血清中sFlt-1为928.13±141.27ng/L,两组比较差异无统计学意义(p>0.05)。2.子痫前期组血清中sEng为7.38±1.78ng/ml正常妊娠组为2.17±0.59ng/ml,两组比较差异有显著性(p<0.01)。重度痫前期组血清中sEng为7.94±1.27ng/ml,轻度痫前期组血清中sEng为5.72±1.09ng/ml,重度子痫前期与轻度子痫前期比较,差异有显著性(p<0.01)。血清中sEng的水平随疾病病情的加重而升高。3.子痫前期组胎盘组织中Endoglin的平均光密度为0.462±0.057,正常妊娠组为0.219±0.042,两组比较差异有显著性(p<0.01);轻度子痫前期组胎盘组织中Endoglin的平均光密度为0.382±0.035,重度子痫前期组胎盘组织中Endoglin的平均光密度为0.488±0.054,两组比较差异有显著性(p<0.01)。子痫前期胎盘组织中Endoglin的平均光密度随疾病病情的加重而升高。4.相关性分析:胎盘组织中Endoglin的平均光密度与血清中sEng的水平呈正相关关系(r>0.9,p<0.01)。血清中sEng的水平随胎盘组织中Endoglin的平均光密度的增强而升高。结论:sEng在子痫前期患者的外周血中高表达,sEng升高的水平与子痫前期临床症状的严重程度呈正相关,其升高程度能反映疾病的严重程度。sFlt-1在子痫前期患者的外周血中高表达,但与子痫前期的严重程度没有直接关系。因此我们认为升高的sFlt-1和sEng共同参与了子痫前期的病理生理过程,但它们分别有不同的作用。Endoglin蛋白在子痫前期胎盘中的表达增高,它随着疾病病情的加重而逐渐升高。而且胎盘中Endoglin蛋白表达水平与血清中sEng浓度呈明显的正相关关系,提示sEng可能主要是由胎盘分泌进入母体循环的。
Objective:By observing the level of serum soluble fins-like tyrosine kinase-1(sFlt-1),soluble Endoglin (sEng) and the expression of Endoglin in placenta in patients with preeclampsia to investigate their roles in patients with preeclampsia and the correlation these parameters with severity degree of preeclampsia. Methods:40 patients in Department of Obstetrics of the Affiliated Hospital of Lu Zhou Medical College were collected from October 2008 to October 2009.Among the 40 patients,10 cases were mild preeclampsia and 30 cases were sever preeclampsia according to the diagnostic and classification criteria based on "Obstetrics and Gynecology"(edited by Lejie, the seventh edition).40 healthy pregnant women were selected as the control group over the same period. The serum level of sFlt-1 and sEng were measured by using enzyme-linked immune-sorbent assay (ELISA) in 40 patients with preeclampsia and 40 control group.So we can learn whether there is difference in the serum level of sFlt-1 and sEng between the two groups. Immunohistochemistry SP method was used to detect the expressions of Endoglin protein in preeclampsia placentas and in normal placentas.So we can learn whether there is difference in the expression of Endoglin between the two groups and learn the relationship between the expression of Endoglin in the placenta and sEng in the serum. Datum were represented by mean±standard deviation(x±s).The result were analyzed using Independent-Samples T Test and Pearson Correlation Test by SPSS 14.0 statistic software. There was a statistical significance when the P value less than the 0.01 level. Result:1.The level of sFlt-1 in the serum was 939.27±109.48ng/L in preeclampsia group and 279.24±147.39ng/L in normal group.Serum sFlt-1 levels in patients with preeclampsia significantly higher than those in controls(p<0.01).The level of sFlt-1 in maternal serum was 941.76±159.01ng/L in sever preeclampsia group and 928.13±141.27ng/L in mild preeclampsia group.There were no statistical significant difference in serum sFlt-1 among patients with preeclampsia(p>0.05).2. The level of sEng in the serum was 7.38±1.78ng/ml in preeclampsia group and 2.17±0.59ng/ml in normal group.Serum sEng levels in patients with preeclampsia significantly higher than those in controls(p<0.01).The level of sEng in maternal serum was 7.94±1.27ng/ml in sever preeclampsia group and 5.72±1.09 ng/ml in mild preeclampsia group.The sEng levels were higher in severe preeclampsia compared to mild. There was a significant difference in serum sEng among patients with preeclampsia(p<0.01).Serum sEng levels increased in accordance with the severity of preeclampsia.3.The mean optical density of Endoglin protein expressed in placenta was 0.462±0.057 in preeclampsia group and 0.219±0.042 in normal group. The mean optical density of Endoglin protein expressed in placenta in preeclampsia group was significantly higher than those in control group (p<0.01);The mean optical density of Endoglin protein expressed in placenta was 0.382±0.035 in mild preeclampsia group and 0.488±0.054 in sever preeclampsia group.The mean optical density of Endoglin protein expressed in placenta was significant higher in severe preeclampsia compared to mild.(p<0.01).The mean optical density of Endoglin protein expressed in placenta increased in accordance with the severity of preeclampsia.4.Correlation analyses showed the levels of the mean optical density of Endoglin protein expressed in placenta had a positive correlation with serum sEng levels(r>0.9,p<0.01).Serum sEng levels increased in accordance with the increase of the mean optical density of Endoglin protein expressed in placenta. Conclusion:Serum sEng level was significantly increased in patients with preeclampsia and increased with the severity degree of diseases.Serum sFlt-1 level was significantly increased in patients with preeclampsia. However it is not directly related to the severity of preeclampsia. We conclude that elevated sFlt-1 and sEng are involved in the pathogenesis of preeclampsia with cooperative, but different roles.The expression of Endoglin protein in placenta was significantly increased in patients with preeclampsia and increased with the severity degree of diseases.The expression of Endoglin protein in placenta had a positive correlation with serum sEng levels, indicating that sEng in the maternal circulation probably was secreted mainly by the placenta.
引文
1.Redman CW, and Sargent IL. Latest advances in understanding preeclampsia [J].Science.2005(5728);308:1592-1594
2.Espinoza J, Romero R, Nien JK,et al.Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor [J]. Am. J. Obstet. Gynecol.2007;196(4):326.e1-326.13
3.Bellamy L, Casas JP, Hingorani AD,et al.Pre-eclampsia and risk of cardiovascular disease and cancer in later life:systematic review and meta-analysis [J].BMJ.2007;335(7627):974
4.Pijnenborg R,Vercruysse L,Hanssens M. The uterine spiral arteries in human pregnancy:facts and controversies [J].Placenta 2006;27(9-10):939-958.
5.Lyall F..Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-eclampsia [J].Aust N Z J Obstet Gynaecol 2006;46(4)266-273
6.Red-horse K,Zhou Y,Genbacev O,et al.Trophoblast differentiation during embryo implantation and formation of the matema-fetal interface [J].J Clin Invest,2004;114(6):744-754.
7.Solemanlou N,Jurisica l,Nevo O,et al.Molecular evidence of placental hypoxia in preeclampsia [J].J Clin Endoerinol Metab.2005;90(7);4299-4308.
8.Park CW, Park JS,Shim SS,An elevated maternal plasma, but not amniotic fluid, soluble fins-like tyrosine kinase-1 (sFlt-1)at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia [J].Am J Obstet Gynecol 2005;193(3Pt2):984-989.
9.Woolcock J, Hennessy A,Xu B,et al.Soluble Flt-1 as a diagnostic marker of preeclampsia [J].Aust N Z J Obstet Gynaecol 2008;48(1):64-70.
10.Maynard SE,Venkatesha S,Thadhani R,et al.Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia [J].Pediatr Res,2005;57(5pt2):1R-7R.
11.Nagamatsu T,Fujii T,Kusumi M,et al.Cytotrophohlasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia [J].Endoelinology,2004;145(11): 4838-4845.
12.Ahmad S,Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia [J].Circ Res,2004;95(9):884-891.
13.Makris A, Thornton C,Thompson J, et al.Uteroplacental ischemia results in proleinuric hypertension and elevated sFLT-1 [J].Kidney Int,2007;71(10):977-984.
14.Maynard SE, Min JY, Merchan J, et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1)may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia [J].J Clin Invest,2003;111(5):649-658.
15.Sugimoto H, Hamano Y, Charytan D, et al.Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria [J].J Biol Chem.2003;278(15):12605-12608
16.Eremina V, Sood M, Haigh J, et al.Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases[J].J Clin Invest,2003;111(5):707-716.
17.Yang JC, Haworth L, Sherry RM, et al.A randomized trial of beva-cizumab,an anti-vascular endothelial growth factor, antibody,for matastat-ic renal cancer [J].N Engl J Med 2003;349(5):427-434
18.Kabbinavar F, Hurwitz HI,Fehrenbacher L, et al.Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil(FU)/ leucovorin(LV) with Fu/LV alone in patients with metastatic colorectal cancer[J] J Clin Oncol,2003,21(1):60-65.
19.Kim YN, Lee DS,Jeong DH, et al.The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia [J].Prenat Diagn,2009;29(5):464-470
20.邢静,陈丽君,Soluble endoglin和sFlt-1在子痫前期患者血清中的表达[J].山东大学学报,2008;45(11):1095-1097
21.Seon BK,Matsuno F,Haruta Y et al.long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vaseulature with antihuman endoglin immunotoxin [J] Clin Cancer Res,1997;3(7):1031-1044.
22.Toporsian M, Gros R, Kabir MG, et al.A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia [J].Circ Res,2005;96 (6): 684-692.
23.Romero R, Nien JK,Espinoza J, A longitudinal study of angiogenic(plaeental Growth factor)and anti-angiogenic(soluble endoglin and soluble vascular Endothelial growth factor receptor-1)factor in normal Pregnancy and patients destined to develop preeclampsia and delivery a small for gestational age neonate [J].J Matern Fetal Neonatal Med.2008;21(1):9-23.
24.Velasco Loyden G,Arribas J,Lopez Casillas F, The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1 [J].J Biol Chem,2004;279(9): 7721-7733.
25.Venkatesha S,Toporsian M, Lam C,et al.Soluble endoglin contributes to the pathogenesis of preeclampsia [J].Nat Med, 2006;12(6):642-649
26.Levine RJ, Maynard SE, Qian C, et al.Circulating angiogenic factors and the risk of preeclampsia[J].N Engl J Med,2004; 350(7):672-683.
27.Masuyama H, Nakatsukasa H, Takamoto N, et al. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1,and adipocytokines in preeclampsia [J].J Clin Endocrinol Metab,2007;92(7):2672-2679.
28.Sanchez Elsner T,Botella LM,Velasco B,et al.Endoglin expression is regulate By transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways[J].J Biol Chem. 2002;277(46):43799-43808.
29.Nevo O,Soleymanlou N,Wu Y, et al.Inereased expression of sFlt-1 in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 [J].Am J Physiol Regul Integr Comp Physiol.2006; 291(4):R1085-R1093.
30.Gu Y,Lewis DF,Wang Y.Placental productions and expressions of soluble Endoglin,soluble fms-like tyrosine kinase receptor-1,and placenial growth factor In normal and preeclamptic pregnaneies [J].J Clin Endocrinol Metab.2008;93(1):260-6.
30.Roberts JM, Gammill HS.Preeclamps:recent insights [J]. Hypertension,2005;46(6):1243-1249.
31.Levine RJ, Maynard SE, Qian c,et al.Circulating angiogenic factors and the risk of preeclampsia[J].N Engl J Med,2004; 350(7):672-683.
32.Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia [J].N Engl J Med,2006;355(10):992-1005.
33.Robinson CJ, Johnson DD.Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol [J].2007;197(2): 174.el-174.e5.
34.Stepan H, Geipel A, Schwarz F, et al.Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion [J].Am J Obstet Gynecol,2008;198(2):175e.1-6.
35.Crispi F, Dominguez C, Llurba E,et al.Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction [J].Am J Obstet Gynecol.2006;195(1):201-207.
1.Redman CW, and Sargent IL. Latest advances in understanding preeclampsia [J].Science.2005,308:1592-1594
2.Espinoza J, Romero R, Nien JK,et al.Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor [J].Am.J. Obstet. Gynecol.2007,196:326.e1-326.e13
3.Bellamy L, Casas JP, Hingorani ADand Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis [J].BMJ.2007,335,974
4. Muy-Rivera M, Vadachkoria S, Woelk G, et al.Maternal plasma VEGF, sVEGF-R1,and P1GF concentrations in preeclamptic and normotensive pregnant zimbabwean women [J].Physiol Res, 2005,54(6):611-622
5.Venkatesha S,Toporsian M, Lam C,et al.Soluble endoglin contributes to the pathogenesis of preeclampsia [J].Nat Med. 2006,12:642-649.
6.Crispi F, Dominguez C,Llurba E,et al.Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol [J].2006,195:201-207.
7.Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia[J].N Engl J Med.2006,355:992-1005.
8.Maynard SE, Min JY, Merchan J, et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia [J].J Clin Invest,2003,111(5):649-658.
9.Sugimoto H, Hamano Y, Charytan D,et al.Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria [J].J. Biol.Chem.2003,278:12605-12608
10.Cudmore M, Ahmad S,Al-Ani B, et al.Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1 [J].Circulation 2007,115:1789-1797
11.Ahmed A, Rahman M, Zhang X, et al.Induction of placental heme oxygenase-1 is protective against TNFα-induced cytotoxicity and promotes vessel relaxation [J].Mol Med.2000,6:391-409
12.Dulak J, Deshane J, Jozkowicz A et al.Heme oxygenase-1 and carbon monoxide in vascular pathobiology:focus on angiogenesis [J].Circulation.2008,117:231-241
13.Bainbridge SA, Smith GN. HO in pregnancy [J].Free Radic Biol Med.2005,38:979-988.
14.Hendler I,Baum M,Kreiser D,et al.End-tidal breath carbon monoxide measurements are lower in pregnant women with uterine contractions[J].J Perinatol.2004,24:275-278.
15.Baum M,Schiff E,Kreiser D,et al.End-tidal carbon monoxide measurements in women with pregnancy-induced hypertension and preeclampsia [J].Am J Obstet Gynecol.2000,183:900-903.
16.Bergmann A, Ahmad S,Cudmore M,et al.Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model[J].J Cell Mol Med.2009, doi:10.1111/j.1582-4934. 2009.00820.x
17.Conde-Agudelo A, Althabe F, Belizan JM ey al.Cigarette smoking during pregnancy and risk of preeclampsia:a systematic review. [J] Am. J. Obstet. Gynecol.1999,181:1026-1035
18.Sidle EH, Casselman R. and Smith GN.Effect of cigarette smoke on placental antioxidant enzyme expression [J].Am. J. Physiol. Regul.Integr. Comp.Physiol.2007,293:R754-R758
19.Mehendale R, Hibbard J, Fazleabas A. and Leach R. Placental angiogenesis markers sFlt-1 and PlGF:response to cigarette smoke [J].Am. J.Obstet. Gynecol.2007,197:363.e1-363.e5
20.Thom SR, Fisher D, Xu YA,et al.Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide [J].Proc.Natl. Acad. Sci.U.S.A.2000,97:1305-1310
21.Farina A, Sekizawa A, De Sanctis P,et al.Gene expression in chorionic villous samples at 11 weeks'gestation from women destined to develop preeclampsia [J].Prenat. Diagn.2008, 28:956-961
22.Ford I, Murray H, Packard CJ,et al.Long-term follow-up of the West of Scotland Coronary Prevention Study [J].N Engl J Med. 2007,357:1477-1486
23.Ofori B, Rey E, and Berard A,et al.Risk of congenital anomalies in pregnant users of statin drugs [J].Br. J. Clin. Pharmacol.2007,64: 496-509
24.Muchova L, Wong RJ, Hsu M, ey al. Statin treatment increases formation of carbon monoxide and bilirubin in mice:a novel mechanism of in vivo antioxidant protection [J].Can J Physiol Pharmacol.2007,85:800-810
25.Baumann MU, Bersinger NA, Surbek DV.Serum markers for predicting pre-eclamp sia [J].Mol Aspecs Med,2007,28 (2): 227-244.
26.Salahuddin S,Lee Y, VadnaisM, et al.Diagnostic utility of soluble Fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy [J].Am J Obstet Gynecol,2007,197(1):28. el-28.e6.